Capot Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (571) 8558-6718 +86 13336195806 | |||
![]() |
capotchem@gmail.com sales@capotchem.com | |||
![]() |
QQ chat | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2006 | ||||
Nanjing Finetech Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (25) 5207-8417 +86 17714198479 | |||
![]() |
sales@fine-chemtech.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2007 | ||||
chemBlink standard supplier since 2007 | ||||
ShangHai PuYi Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (21) 5768-7505 ex 305 +86 13601674297 +86 15601977133 | |||
![]() |
sales@gyrochem.com annafan@gyrochem.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2008 | ||||
chemBlink standard supplier since 2008 | ||||
Anhui Lianchuang Biological Medicine Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (551) 6859-6228 6859-6338 +86 15856900656 | |||
![]() |
sales@lcywhx.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2009 | ||||
chemBlink standard supplier since 2009 | ||||
Changzhou Carbochem Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (519) 8918-1862 +86 13775204319 | |||
![]() |
gao@carbo-chem.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2009 | ||||
chemBlink standard supplier since 2010 | ||||
Xuchang Chenhe Bio-pharmaceutical Tech. Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (374) 579-3128 +86 15836530076 | |||
![]() |
wxh5168@126.com wxh5168@163.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2012 | ||||
chemBlink standard supplier since 2013 | ||||
Changzhou Yuanda Pharmaceutical Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (519) 8398-4084 +86 13776846168 | |||
![]() |
sales@ydpharm.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2012 | ||||
chemBlink standard supplier since 2014 | ||||
Amadis Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (571) 8992-5085 | |||
![]() |
sales@amadischem.com | |||
Chemical manufacturer since 2010 | ||||
chemBlink standard supplier since 2015 | ||||
Classification | Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound |
---|---|
Name | 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine |
Synonyms | 4-Chloro-7-(4-methylphenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine |
Molecular Structure | ![]() |
Molecular Formula | C13H10ClN3O2S |
Molecular Weight | 307.76 |
CAS Registry Number | 479633-63-1 |
EC Number | 811-000-2 |
SMILES | CC1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2N=CN=C3Cl |
Density | 1.49 |
---|---|
Hazard Symbols |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H315-H319 Details | ||||||||||||||||
Precautionary Statements | P264-P264+P265-P280-P302+P352-P305+P351+P338-P321-P332+P317-P337+P317-P362+P364 Details | ||||||||||||||||
Hazard Classification | |||||||||||||||||
| |||||||||||||||||
SDS | Available | ||||||||||||||||
The discovery of 4-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine stems from the development of novel pyrrolopyrimidine derivatives with enhanced biological properties. The researchers aimed to combine the structural features of pyrrolopyrimidine, a scaffold known for its pharmacological potential, with the reactivity of chlorine and tosyl groups. The synthesis of the compound involves a multistep process involving cyclization of appropriate precursors and subsequent chlorination and mesylation steps. The typical approach involves starting from a pyrimidine derivative, introducing the chlorine substituent via electrophilic aromatic substitution, and attaching the mesylate group using mesyl chloride. 4-Chloro-7-mesyl-7H-pyrrolo[2,3-d]pyrimidine is a key intermediate in the synthesis of drugs, particularly those targeting kinases. Kinase inhibitors are an important class of drugs used in cancer therapy, as they can selectively inhibit enzymes involved in cellular signaling pathways that are critical for cancer cell growth and survival. The structural features of this compound allow it to participate in the formation of kinase inhibitors as a core building block, allowing the introduction of various functional groups to generate compounds with specific inhibitory activities. Furthermore, the tosyl group of this compound can serve as a protecting or leaving group, facilitating further modifications of complex synthetic pathways. This makes 4-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine a versatile tool in medicinal chemistry for the development of a variety of therapeutic agents, including anticancer drugs and other bioactive molecules. In organic synthesis, 4-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine is valued for its reactivity, which can be used to build more complex molecules. The presence of the chloro group allows for nucleophilic substitution reactions, while the tosyl group provides control over a variety of transformations, including deprotection or coupling reactions. This versatility makes it a useful intermediate for the synthesis of heterocyclic compounds, which are important in medicinal chemistry and materials science. The ability of this compound to serve as a key intermediate in the construction of a variety of chemical entities highlights its role in the development of new methods for the synthesis of complex organic molecules. Its inclusion in multistep synthetic schemes expands the toolkit of synthetic chemists for the creation of new compounds. Ongoing research focuses on optimizing its synthesis and exploring its potential in developing new drugs and materials. Research aims to improve the efficiency of its synthetic routes, increase yields and shorten reaction times. In addition, research on its applications will continue to discover new possibilities in creating advanced materials and therapeutic agents, driving innovation in academic and industrial fields. |
Market Analysis Reports |
List of Reports Available for 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine |